Polyclonal Antibody to Epithelial Neutrophil Activating Peptide 78 (ENA78)
Code | Size | Price |
---|
PAA860Mu01-20ul | 20ul | £82.00 |
Quantity:
PAA860Mu01-100ul | 100ul | £152.00 |
Quantity:
PAA860Mu01-200ul | 200ul | £204.00 |
Quantity:
PAA860Mu01-1ml | 1ml | £464.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CXCL5; SCYB5; Chemokine C-X-C-Motif Ligand 5; Small Inducible Cytokine Subfamily B(Cys-X-Cys),Member 5; Neutrophil-activating peptide ENA-78
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Epithelial Neutrophil Activating Peptide 78
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
References
https://www.ncbi.nlm.nih.gov/pubmed/30634975; https://wwwncbi.53yu.com/pmc/articles/pmc8822283/;
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Epithelial Neutrophil Activating Peptide 78 (ENA78) | RPA860Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||